Novartis hopes a CAR-T with rapid manufacturing will be a winner, while novel bispecific antibodies in lymphoma and myeloma will make appearances, along with next-generation PI3K and BTK inhibitors.

Data from SHORELINE’s 50mg cohort sparked mixed opinions from analysts, with some suggesting they still showed a risk-benefit profile that could challenge the drug commercially.

PI3K-delta inhibitors have often suffered from safety and tolerability issues, but Phase II data show higher efficacy and lower discontinuation rates for zandelisib than others in the class.

The approval of Fyarro marks the first for advanced malignant PEComa, a rare cancer that affects only 100-300 people in the US; it's also the first launch for Aadi Biosciences.

Early clinical results for AFM13 combined with NK cells showed high response rates without serious toxicities, and the data could have readthrough to the company’s EGFR-targeted therapy.

Pfizer CEO Albert Bourla discussed the emergency use authorization filing for Paxlovid, expanding access to the COVID-19 pill in lower income countries and booster shots, at the STAT Summit.